Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry

Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease-specific treatment is available in the form of enzyme replacement therapy wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Muenzer, Joseph, Jones, Simon A., Tylki-Szymańska, Anna, Harmatz, Paul, Mendelsohn, Nancy J., Guffon, Nathalie, Giugliani, Roberto, Burton, Barbara K., Scarpa, Maurizio, Beck, Michael, Jangelind, Yvonne, Hernberg-Stahl, Elizabeth, Larsen, Maria Paabøl, Pulles, Tom, Whiteman, David A. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414331/
https://www.ncbi.nlm.nih.gov/pubmed/28464912
http://dx.doi.org/10.1186/s13023-017-0635-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414331/
https://www.ncbi.nlm.nih.gov/pubmed/28464912
http://dx.doi.org/10.1186/s13023-017-0635-z

Ejemplares similares